EFFECT OF A SINGLE INTRAMUSCULAR DOSE OF VITAMIN D ON CONCENTRATIONS OF LIPOSOLUBLE VITAMINS IN THE PLASMA OF HEIFERS WINTER-FED OAT SILAGE, GRASS SILAGE OR HAY

1980 ◽  
Vol 60 (2) ◽  
pp. 311-318 ◽  
Author(s):  
M. HIDIROGLOU ◽  
M. IVAN ◽  
J. G. PROULX ◽  
J. R. LESSARD
Keyword(s):  
Vitamin D ◽  
Plasma Levels ◽  
Dietary Treatment ◽  
Hydroxyvitamin D ◽  
Intramuscular Dose ◽  
Grass Silage ◽  
Weight Gains ◽  
Calcium Phosphorus ◽  
25 Hydroxyvitamin D ◽  
Blood Profiles

Blood profiles for 25 hydroxyvitamin D (250HD), vitamins A and E, calcium, phosphorus and magnesium in three groups of Shorthorn heifers winter-fed either oat silage, grass silage or hay have been established. In each dietary treatment, half of the animals were injected with a single intramuscular dose of vitamin D3 (1 000 000 IU). The injections increased plasma 250HD levels (ng/mL) at the end of the experiment from 35 to 44 for oat silage, from 35 to 75 for grass silage and from 29 to 40 for hay. The plasma 250HD in the oat silage-fed heifers approached levels that were suggestive of vitamin D deficiency. 250HD plasma levels of cattle on grass silage were more responsive to the vitamin D treatment than those on oat silage or hay. Plasma levels of vitamin A at the end of the experiment (134 day s) were significantly higher (P < 0.01) in the silage-fed animals than in the hay-fed animals. The vitamin D-treated heifers fed oat silage had higher (P < 0.05) blood vitamin E levels than the other heifers. Plasma calcium, phosphorus and magnesium levels appeared to be unaffected by diet or vitamin D treatment. Greater weight gains were observed in heifers on hay than in those on grass silage or oat silage. Weight gains tended to be higher (NS) in the vitamin D-treated heifers fed oat silage than in those that were not treated. Gains were also higher (P < 0.05) with the hay than with the silage diets.

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease

2019 ◽  
Vol 49 (4) ◽  
pp. 284-293 ◽  
Author(s):  
Stephen A. Strugnell ◽  
Stuart M. Sprague ◽  
Akhtar Ashfaq ◽  
Martin Petkovich ◽  
Charles W. Bishop
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Hydroxyvitamin D ◽  
Calcium Phosphorus ◽  
Safety Parameters ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively “safety parameters”) did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.

scholarly journals Deficiency of 25-Hydroxyvitamin D and Dyslipidemia in Indian Subjects

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Jaydip Ray Chaudhuri ◽  
K. Rukmini Mridula ◽  
Alluri Anamika ◽  
Demudu Babu Boddu ◽  
Pradeep Kumar Misra ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Vitamin D Deficiency ◽  
Serum Glucose ◽  
C Reactive Protein ◽  
Hydroxyvitamin D ◽  
Reactive Protein ◽  
Calcium Phosphorus ◽  
25 Hydroxyvitamin D ◽  
Chemiluminescent Microparticle Immunoassay

Background. Vitamin D deficiency is widespread throughout the world. Several reports have incriminated vitamin D deficiency as the cause of rickets, osteomalacia, and other chronic diseases. Recent studies have suggested a possible link between deficiency of 25-hydroxyvitamin D and dyslipidemia.Aim. To investigate the association between 25-hydroxyvitamin D deficiency and dyslipidemia in Indian subjects.Methodology. We recruited 150 asymptomatic consecutive subjects from patients’ attendees at the Departments of Neurology and Medicine in Yashoda Hospital, Hyderabad, India. Study period was from October 2011 to March 2012. All subjects underwent 25-hydroxyvitamin D assay by chemiluminescent microparticle immunoassay, fasting blood sugar and lipid profile, calcium, phosphorus, alkaline phosphatase, and C-reactive protein (CRP).Results. Out of 150 subjects, men were 82 (54.6%), and mean age was 49.4 (±15.6) years. Among risk factors, hypertension was noted in 63/150 (42%), 25-hydroxyvitamin D deficiency in 59/150 (39.3%), diabetes in 45/150 (30%), dyslipidemia in 60 (40%), smoking in 35/150 (23.3%), and alcoholism in 27/150 (18%). Deficiency of 25-hydroxyvitamin D was significantly associated with dyslipidemia (P=0.0001), mean serum glucose (P=0.0002) mean CRP (P=0.04), and mean alkaline phosphatase (P=0.01). Multivariate analysis showed that 25-hydroxyvitamin D deficiency was independently associated with dyslipidemia (odds ratio: 1.9; 95% CI : 1.1–3.5).Conclusions. We found that deficiency of 25-hydroxyvitamin D was independently associated with dyslipidemia in Indian subjects.

scholarly journals The Role of the Intraplaque Vitamin D System in Atherogenesis

Scientifica ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-14 ◽  
Author(s):  
Federico Carbone ◽  
Fabrizio Montecucco
Keyword(s):  
Vitamin D ◽  
Clinical Findings ◽  
Peripheral Tissues ◽  
Hydroxyvitamin D ◽  
Dihydroxyvitamin D ◽  
Mouse Tissues ◽  
Calcium Phosphorus ◽  
25 Hydroxyvitamin D ◽  
Physiological Pathways

Vitamin D has been shown to play critical activities in several physiological pathways not involving the calcium/phosphorus homeostasis. The ubiquitous distribution of the vitamin D receptor that is expressed in a variety of human and mouse tissues has strongly supported research on these “nonclassical” activities of vitamin D. On the other hand, the recent discovery of the expression also for vitamin D-related enzymes (such as 25-hydroxyvitamin D-1α-hydroxylase and the catabolic enzyme 1,25-dihydroxyvitamin D-24-hydroxylase) in several tissues suggested that the vitamin D system is more complex than previously shown and it may act within tissues through autocrine and paracrine pathways. This updated model of vitamin D axis within peripheral tissues has been particularly investigated in atherosclerotic pathophysiology. This review aims at updating the role of the local vitamin D within atherosclerotic plaques, providing an overview of both intracellular mechanisms and cell-to-cell interactions. In addition, clinical findings about the potential causal relationship between vitamin D deficiency and atherogenesis will be analysed and discussed.

scholarly journals 25-Hydroxyvitamin D, IL-31, and IL-33 in Children with Allergic Disease of the Airways

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Anna Bonanno ◽  
Sebastiano Gangemi ◽  
Stefania La Grutta ◽  
Velia Malizia ◽  
Loredana Riccobono ◽  
...  
Keyword(s):  
Vitamin D ◽  
Allergic Rhinitis ◽  
Allergic Asthma ◽  
Allergic Disease ◽  
Plasma Levels ◽  
Disease Duration ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Low Levels ◽  
Blood Eosinophils

Low vitamin D is involved in allergic asthma and rhinitis. IL-31 and IL-33 correlate with Th2-associated cytokines in allergic disease. We investigated whether low vitamin D is linked with circulating IL-31 and IL-33 in children with allergic disease of the airways. 25-Hydroxyvitamin D [25(OH) Vit D], IL-31, and IL-33 plasma levels were measured in 28 controls (HC), 11 allergic rhinitis (AR) patients, and 35 allergic asthma with rhinitis (AAR) patients. We found significant lower levels of 25(OH) Vit D in AR and in AAR than in HC. IL-31 and IL-33 plasma levels significantly increased in AAR than HC. IL-31 and IL-33 positively correlated in AR and AAR. 25(OH) Vit D deficient AAR had higher levels of blood eosinophils, exacerbations, disease duration, and total IgE than patients with insufficient or sufficient 25(OH) Vit D. In AAR 25(OH) Vit D levels inversely correlated with total allergen sIgE score and total atopy index. IL-31 and IL-33 did not correlate with 25(OH) Vit D in AR and AAR. In conclusion, low levels of 25(OH) Vit D might represent a risk factor for the development of concomitant asthma and rhinitis in children with allergic disease of the airways independently of IL-31/IL-33 Th2 activity.

scholarly journals The Relationship of 25-Hydroxyvitamin D Plasma Levels with Breast Cancer Stadium Assessed from Menopause Status

2021 ◽  
Vol 3 (1) ◽  
pp. 65-72
Author(s):  
Ika Waraztuty ◽  
Astrid Siska Pratiwi ◽  
Melya Susanti ◽  
Ira Astuti ◽  
Zakirullah
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Plasma Levels ◽  
Menopausal Status ◽  
Observational Research ◽  
Cancer Stage ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Post Menopausal ◽  
The Relationship

Breast cancer is a type of cancer with high incidence and mortality especially in developing countries. Vitamin D regulates the expression a number of genes involved in the development of cancer cells. The aim of this study is to analyze the relationship between 25-hydroxyvitamin D (25 (OH) D) plasma level with breast cancer stage based on menopausal status. This is an observational research method with cross sectional design. Research subjects were 53 newly diagnosed breast cancer patients and had not received chemotherapy. Menopausal status and stage data were obtained from interviews and medical record data. Levels of 25-hydroxyvitamin D plasma were measured (ELISA) method. The results obtained Stage II, III and IV each have an average level of vitamin D of 28,56 ng/ml (95% CI; 23,61 – 33,52 ng/ml),  28,18 ng/ml (95% CI: 24,49 – 31,87 ng/ml) and  27,86 ng/ml  (95% CI: 22,68 – 33,04 ng/ml).The average plasma concentration of 25 (OH) D in pre-menopausal patients is 28,54 ng/ml and average plasma 25 (OH) D levels in post-menopausal patients is 27,79 ng/ml. There was no significant relationship between plasma levels of 25 (OH) D and breast cancer stage in both pre-menopausal and post-menopausal patients.

Plasma levels of vitamin D and some metabolites in marine mammals

1988 ◽  
Vol 66 (6) ◽  
pp. 1297-1300 ◽  
Author(s):  
K. M. Keiver ◽  
K. Ronald ◽  
H. H. Draper
Keyword(s):  
Vitamin D ◽  
Plasma Levels ◽  
Marine Mammals ◽  
Plasma Calcium ◽  
Cetacean Species ◽  
Hydroxyvitamin D ◽  
Dihydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Very High

Levels of vitamin D, 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and calcium were determined in the plasma of various captive and wild pinniped and cetacean species. Vitamin D (< 0.4–5 ng∙mL−1) and 25-hydroxyvitamin D (4–84 ng∙mL−1) levels in the pinniped plasma were similar to those found in nonmarine mammals. 24,25-Dihydroxyvitamin D levels in seals (3–48 ng∙mL−1) were high compared with those of other mammals, and the ratios of 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D in fasting pups were extremely high. The belugas and bottlenosed dolphins had very high levels of both 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D compared with the pinnipeds and other mammals, but plasma calcium levels were normal for these species of cetaceans.

scholarly journals Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 130
Author(s):  
Giulia Bivona ◽  
Caterina Maria Gambino ◽  
Bruna Lo Sasso ◽  
Concetta Scazzone ◽  
Rosaria Vincenza Giglio ◽  
...  
Keyword(s):  
Vitamin D ◽  
Autoimmune Diseases ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Hydroxyvitamin D ◽  
Serum Vitamin D ◽  
Immune Mediated ◽  
Calcium Phosphorus ◽  
25 Hydroxyvitamin D ◽  
Meta Analyses

Vitamin D is a steroid hormone regulating calcium-phosphorus homeostasis, immune response and brain function. In the past thirty years, an increasing number of cohort studies, meta-analyses and randomized controlled trials (RTCs) evaluated the serum levels of 25-hydroxyvitamin D [25(OH)D], which is considered the Vitamin D status biomarker, in patients affected by neurological, psychiatric and autoimmune diseases. Although an association between low 25(OH)D serum levels and the prevalence of these diseases has been found, it is still unclear whether the serum 25(OH)D measurement can be clinically useful as a biomarker for diagnosis, prognosis and predicting treatment response in neurodegeneration, mental illness and immune-mediated disorders. The lack of standardized data, as well as discrepancies among the studies (in the analytical methods, cut-offs, endpoints and study sets), weakened the findings achieved, hindered pooling data, and, consequently, hampered drawing conclusions. This narrative review summarizes the main findings from the studies performed on serum 25(OH)D in neurological, psychiatric and autoimmune diseases, and clarifies whether or not serum 25(OH)D can be used as a reliable biomarker in these diseases.

Does sufficient 25-hydroxyvitamin D mean lower metabolic risk for women?

2020 ◽  
Vol 13 (4) ◽  
pp. 311-318
Author(s):  
Zeynep Cetin ◽  
Ozden Baser ◽  
Derya Koseoglu ◽  
Merve Catak
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Metabolic Diseases ◽  
Thyroid Stimulating Hormone ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
Calcium Phosphorus ◽  
25 Hydroxy Vitamin D ◽  
25 Hydroxyvitamin D ◽  
25 Oh Vitamin D

OBJECTIVE: There are conflicting results regarding the relationship between metabolic diseases and vitamin D deficiency. We aimed to show the possible relationship between 25-hydroxy (OH) vitamin D levels and obesity, insulin resistance and hyperlipidemia in women. MATERIALS AND METHODS: Three hundred fifty seven female were included retrospectively. Body mass index (BMI) was determined with body weight (kg)/height (m2) formula. Fasting plasma glucose, insulin, lipid profile, calcium, phosphorus, parathormone, 25 hydroxy vitamin D, thyroid stimulating hormone were evaluated. Insulin resistance was calculated with homeostatic model values for insulin resistance (HOMA-IR). Patients were grouped according to 25 (OH) vitamin D levels and BMIs. RESULTS: 25 (OH) vitamin D was negative correlated with BMI, insulin and HOMA-IR, (respectively r = –0.156, –0.128, –0.123 and p = 0.003, 0.015, 0.020). It is positive correlated with HDL and HDL/LDL ratio (respectively r = 0.183, 0.185 and p = 0.003, <0.001) HDL-C was higher in 25(OH) vitamin D sufficient group. After multivariate analysis, 25 (OH) vitamin D was still positively related with HDL and HDL/LDL ratio (respectively r = 0.127, 0.118 and p = <0.05). CONCLUSION: 25 (OH) Vitamin D is relationship with HDL, HDL/LDL ratio and invers relationship obesity. The normal 25 (OH) vitamin D supports the reduction of metabolik risk.

scholarly journals An Unusual Case of Hypercalcemia Associated with Graves’ Disease and Vitamin D Deficiency

2011 ◽  
Vol 4 ◽  
pp. CMED.S7116 ◽  
Author(s):  
Evgenia Korytnaya ◽  
Nagashree Gundu Rao ◽  
Jane V. Mayrin
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Vitamin D Deficiency ◽  
Serum Calcium ◽  
Graves Disease ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
Calcium Phosphorus ◽  
25 Hydroxyvitamin D ◽  
25 Oh Vitamin D

Objective To present a case of hypercalcemia associated with thyrotoxicosis in a patient with vitamin D deficiency and review biochemical changes during the course of treatment. Methods We report a case, describe the changes in serum calcium, phosphorus, parathyroid hormone in Graves’ disease and concomitant Vitamin D deficiency. We compare our findings to those reported in literature. Results Our patient had hypercalcemia secondary to thyrotoxicosis alone, which was confirmed by low parathyroid hormone level and resolution of hypercalcemia with treatment of thyrotoxicosis. The case was complicated by a concomitant vitamin D deficiency. Serum calcium elevation in patients with thyrotoxicosis occurs secondary to hyperthyroidism alone or due to concurrent hyperparathyroidism. Hypercalcemia from thyrotoxicosis is usually asymptomatic and is related to bone resorption. Vitamin D deficiency can be seen in patients with thyrotoxicosis because of accelerated metabolism, poor intestinal absorption and increased demand during bone restoration phase. Coexistence of hypercalcemia and Vitamin D deficiency in patients with thyrotoxicosis is rare, but possible, and 25-hydroxyvitamin D levels should be checked. The definite treatment for hypercalcemia in thyrotoxicosis is correction of thyroid function. Conclusion Hypercalcemia in thyrotoxicosis should be distinguished from concomitant hyperparathyroidism and confirmed by resolution of hypercalcemia with control of thyrotoxicosis. Patients with hypercalcemia and thyrotoxicosis may also have vitamin D deficiency and 25-OH Vitamin D levels should be checked.

scholarly journals Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism

2008 ◽  
Vol 159 (6) ◽  
pp. 719-727 ◽  
Author(s):  
Signe Engkjær Christensen ◽  
Peter H Nissen ◽  
Peter Vestergaard ◽  
Lene Heickendorff ◽  
Lars Rejnmark ◽  
...  
Keyword(s):  
Vitamin D ◽  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Plasma Levels ◽  
Familial Hypocalciuric Hypercalcemia ◽  
Vitamin D Metabolism ◽  
Hydroxyvitamin D ◽  
Dihydroxyvitamin D ◽  
1,25 Dihydroxyvitamin D ◽  
25 Hydroxyvitamin D

IntroductionFamilial hypocalciuric hypercalcemia (FHH) is a lifelong, benign, inherited condition caused by inactivating mutations in the calcium-sensing receptor (CASR) gene. Both FHH and primary hyperparathyroidism (PHPT) are characterized by elevated P-calcium, normal or elevated plasma-parathyroid hormone (P-PTH), and typically normal renal function. In PHPT, vitamin D metabolism is typically characterized by low plasma levels of 25-hydroxyvitamin D (25OHD), and high plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D). In FHH, the vitamin D metabolism is not very well known.ObjectiveTo compare and evaluate plasma 25OHD, 1,25(OH)2D, and PTH in FHH and PHPT.DesignCross-sectional study.MaterialsAbout 66 FHH patients with mutations in the CASR gene, 147 patients with surgically verified PHPT, and 46 controls matched to FHH patients according to age (±5 years), sex, and season. All patients had a P-creatinine <140 μmol/l.MethodsWe measured P-calcium, P-Ca2+, P-albumin, P-creatinine, P-phosphate, P-magnesium, and P-PTH by standard laboratory methods. P-25OHD and P-1,25(OH)2D were measured by RIA or enzyme immunoassay. In FHH, all protein-coding exons in the CASR gene were sequenced and aligned to GenBank reference sequence .ResultsPHPT patients had higher body mass index (2p<0.01), together with higher P-PTH (2p<0.01) and P-1,25(OH)2D (2p<0.01) compared with FHH patients. The groups had similar levels of P-Ca2+ and of P-25OHD. The phenotypic expression of the CASR mutations (as determined by the degree of hypercalcemia) did not influence the levels of P-1,25(OH)2D.ConclusionEven though P-calcium and P-25OHD were comparable, P-1,25(OH)2D and P-PTH differed between FHH and PHPT.

Sign in / Sign up

Export Citation Format

Share Document